Edesa Biotech Past Earnings Performance
Past criteria checks 0/6
Edesa Biotech's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 72.1% per year.
Key information
-14.4%
Earnings growth rate
4.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -72.1% |
| Return on equity | -241.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08
Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03Revenue & Expenses Breakdown
How Edesa Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | 5 | 4 |
| 31 Mar 24 | 0 | -7 | 5 | 4 |
| 31 Dec 23 | 0 | -8 | 5 | 4 |
| 30 Sep 23 | 0 | -8 | 4 | 5 |
| 30 Jun 23 | 0 | -9 | 4 | 6 |
| 31 Mar 23 | 0 | -13 | 4 | 9 |
| 31 Dec 22 | 0 | -16 | 5 | 11 |
| 30 Sep 22 | 0 | -18 | 5 | 13 |
| 30 Jun 22 | 0 | -18 | 5 | 16 |
| 31 Mar 22 | 0 | -17 | 6 | 16 |
| 31 Dec 21 | 0 | -15 | 6 | 21 |
| 30 Sep 21 | 0 | -13 | 6 | 18 |
| 30 Jun 21 | 0 | -12 | 5 | 15 |
| 31 Mar 21 | 0 | -9 | 4 | 12 |
| 31 Dec 20 | 0 | -8 | 4 | 4 |
| 30 Sep 20 | 0 | -6 | 3 | 3 |
| 30 Jun 20 | 1 | -5 | 3 | 3 |
| 31 Mar 20 | 1 | -5 | 3 | 2 |
| 31 Dec 19 | 1 | -4 | 3 | 2 |
| 30 Sep 19 | 0 | -3 | 2 | 1 |
| 30 Jun 19 | 0 | -3 | 2 | 1 |
| 31 Mar 19 | 0 | -2 | 1 | 1 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
Quality Earnings: EDSA is currently unprofitable.
Growing Profit Margin: EDSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EDSA is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare EDSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: EDSA has a negative Return on Equity (-241.65%), as it is currently unprofitable.